SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harry Lewis who wrote (281)3/8/1998 9:12:00 AM
From: Chris D  Read Replies (1) of 1321
 
Her $45.00 12-month target price is based on:
A) upcoming expected FDA final approval for the use of Photofrin in the treatment of early lung cancer.
B) Photofrin's German & French launch + other European filings with planned approvals in 1998.
C) Phase III BPD for AMD trial completing enrollment on time.
D) QLT is/was trading at a 27% discount (Dec. 12 - $16.70) to other photodynamic therapy companies despite being more advanced and having a stronger financial position.
E) Most of the market valuation for QLT lies in the more attractive AMD market.

Chris
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News